Clinical trials: Allogeneic Transplant
AML, ALL
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects.
- Conditions
- AML, ALL, CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL
- Trial name
- MINI HEME (NCT00636909)
- Testing
- Cyclophosphamide, fludarabine, cyclosporine
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
This phase Ib trial studies the side effects of combination chemotherapy and donor stem cell transplant followed by ixazomib citrate maintenance therapy in treating patients with multiple myeloma that has returned after a period…
- Trial name
- NCT02504359
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Graft Vs Host Disease
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC)…
- Trial name
- NCT00136903
- Testing
- Prochymal® - 2 Million cells/kg, Prochymal®- 8 Million cells/kg, Methylprednisolone
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- Mesoblast, Inc.
Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor
Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors
National and international guidelines/consensus recommend G-CSF (granulocyte colony-stimulating factor) at 10 μg/kg/day as a single daily dose or divided into two daily doses for mobilization in healthy donors for allogeneic…
- Trial name
- NCT07692841
- Testing
- Single-dose Granulocyte colony-stimulating factor (G-CSF), Divided-dose Granulocyte colony-stimulating factor (G-CSF)
- Where
- 8 sites in China
- Volunteers
- 560 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
GVHD,Acute, aGVHD
Safety and Efficacy Study of hAESCs Therapy for aGVHD
Allogeneic hematopoietic stem cell transplantation (allo-HSCT), a process in which hematopoietic stem cells from a donor are injected into the recipient's body, are the treatment of choice for many hematologic malignancies.
- Trial name
- aGVHD，hAESCs (NCT06164288)
- Testing
- Human Amniotic Epithelial Stem Cell Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
CMV Reactivation, Allogeneic Stem Cell Transplantation
Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation
The investigators will assess whether the infusion of autologous CMV-specific T-cells at the time of CMV reactivation posttransplant will prevent worsening of CMV virus reactivation posttransplant to a level that warrants therapy…
- Conditions
- CMV Reactivation, Allogeneic Stem Cell Transplantation, Autologous CMV Specific CD8+ T Cells
- Trial name
- NCT01326273
- Testing
- Lymphopheresis, CMV specific lymphocyte infusion, Peripheral blood for CMV DNA PCR
- Where
- United Kingdom
- Sponsor
- Imperial College London
Chronic Graft Versus Host Disease
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD).
- Trial name
- TIL-GVHD (NCT06247150)
- Testing
- Additional blood sample, cGVHD target tissue biopsy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Bordeaux
Myelodysplastic Syndromes, Acute Myelogenous Leukemia
Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
The hypothesis of this study is that lenalidomide can be an effective drug in preventing relapse of MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q after allogeneic HSCT.
- Trial name
- LENAMAINT (NCT00720850)
- Testing
- lenalidomide
- Where
- 7 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Technische Universität Dresden
Acute Myeloid Leukemia
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem cell transplant,
- Trial name
- RADIUS (NCT01883362)
- Testing
- Midostaurin, Standard of Care
- Where
- 19 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Graft Failure, Poor Graft Function
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft…
- Trial name
- NCT06569082
- Testing
- CD34+ Selected Donor Cell Boost, Blood Stem Cell Infusion
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- NYU Langone Health
Poor Graft Function
Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation
To investigate the efficacy and safety for secondary poor graft function (PGF) post allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary objective is the hematologic response rate.
- Trial name
- NCT03437603
- Testing
- Eltrombopag
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia, Myelodysplastic Syndromes
IFN-α in Relapse Prevention.
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry…
- Trial name
- NCT07449286
- Testing
- IFN-α
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Cardiotoxicity, DPP3
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year.
- Conditions
- Cardiotoxicity, DPP3, HSCT, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- ALLOCARDIOTOX (NCT07157670)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematologic Malignancies
Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies
Patients who have cancer of the bone marrow (leukemia) or lymph gland (lymphomas) are being asked to take part in this study. This study uses a new chemotherapy regimen and matched volunteer stem cell transplant to treat patients…
- Trial name
- NCT00208923
- Testing
- Busulfan, Cyclophosphamide and Fludarabine
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Emory University
Primary Graft Failure
REVEAL Biomarkers of Engraftment After Alternative Donor HSCT
The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed.
- Trial name
- REVEAL (NCT03541889)
- Testing
- FLT imaging and TK1 blood measurements
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00296023
- Testing
- anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of California, San Francisco
Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation
Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
Chronic graft-versus-host disease (cGvHD) is one of the most serious complications following BMT (Bone Marrow Transplantation). cGvHD occurs when donor immune cells "attack" the tissues and organs of the person receiving the BMT.
- Conditions
- Chronic Graft-versus-Host-Disease, Allogeneic Hematopoietic Stem Cell Transplantation, Leukemia, Blood Cancer
- Trial name
- NCT05692713
- Where
- 10 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- University of British Columbia
Hodgkin's Disease
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
The goal of this clinical research study is to learn if fludarabine, melphalan and gemcitabine followed by transplantation of stem cells (blood-forming cells) as well as immune cells (lymphocytes), collected from a matched…
- Trial name
- NCT00385788
- Testing
- Gemcitabine, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute…
- Trial name
- NCT00116467
- Testing
- GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cell Genesys
Lymphoma, Disorder Related to Bone Marrow Transplantation
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
The goal of this clinical research study is to see if receiving a transplant of blood stem cells (cells that can produce blood) or bone marrow from either a related donor (brother, sister or other relative) or an unrelated…
- Trial name
- NCT00506129
- Testing
- Fludarabine, Melphalan, Allogeneic Transplant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center